Document 0094
 DOCN  M95B0094
 TI    Immunogenicity and safety of an inactivated hepatitis A vaccine in
       anti-HIV positive and negative homosexual men.
 DT    9511
 AU    Hess G; Clemens R; Bienzle U; Schonfeld C; Schunck B; Bock HL; I.
       Medical Department, Klinikum der Johannes; Gutenberg-Universitat, Mainz,
       Germany.
 SO    J Med Virol. 1995 May;46(1):40-2. Unique Identifier : AIDSLINE
       MED/95348667
 AB    The immunogenicity, reactogenicity, and safety of an inactivated
       hepatitis A vaccine were assessed in anti-HIV positive homosexual men.
       Fourteen anti-HIV positive (group 1) and 20 anti-HIV negative (group 2)
       men received vaccine (containing 720 ELISA units of hepatitis A antigen
       per dose) intramuscularly at 0, 1, and 6 months. Twelve unvaccinated
       anti-HIV positive men (group 3) were included as controls to evaluate
       disease progression. Seroconversion (anti-hepatitis V virus (HAV) > or =
       20 mlU/ml) was higher in group 2 than group 1 at months 2 (100% vs. 73%)
       and 7 (100% vs. 77%). Group 2 had higher antibody titres than group 1 at
       months 1 (201 vs. 92 mlU/ml) and 7 (1,687 vs. 636 mlU/ml). The decline
       in CD4+ cells between months 0 and 7 was similar in groups 1 and 3 (6.4%
       vs. 16.2%), showing no evidence for harmful effect of the vaccine on the
       course of HIV infection. This hepatitis A vaccine appears safe, well
       tolerated, but less immunogenic in HIV positive homosexual men.
 DE    Acquired Immunodeficiency Syndrome/PREVENTION & CONTROL  Adult  Aged
       Consumer Product Safety  CD4 Lymphocyte Count  CD4-Positive
       T-Lymphocytes/IMMUNOLOGY  Hepatitis A/IMMUNOLOGY/*PREVENTION & CONTROL
       Hepatovirus/IMMUNOLOGY  Homosexuality, Male  Human  HIV
       Seronegativity/IMMUNOLOGY  HIV Seropositivity/*IMMUNOLOGY  Male  Middle
       Age  Vaccines, Inactivated/IMMUNOLOGY  Viral Hepatitis Vaccines/ADVERSE
       EFFECTS/*IMMUNOLOGY  CLINICAL TRIAL  CONTROLLED CLINICAL TRIAL  JOURNAL
       ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).